This control plane turns synthetic pharmacovigilance exports into one review surface: case completeness, seriousness assessment, MedDRA coding, follow-up closure, aggregate reporting evidence, and named signal actions before committee decisions harden around weak packets.
No patient-identifiable, clinician, or sponsor-confidential safety data appears anywhere in this repo or its public API.
Every row in the Signal Lane and Case Routing tables maps to a named pharmacovigilance workflow stage, not a generic status label.
No claim of GVP, FDA, EMA, or pharmacovigilance compliance is made anywhere on this site.
The commercial path is stated once, on the Overview page, not repeated as a call to action on every route.